Showing results (461-470 of 475) with videos related to

Sort By:
Pageof 48
Arthritis Research & Therapy|August 29, 2014
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeuticsGlynn Dennis, Cécile T J Holweg, Sarah K Kummerfeld, et al.
Nature Immunology|March 21, 2019
Activation of naïve CD4<sup>+</sup> T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4<sup>+</sup> T cellsJason P Twohig, Ana Cardus Figueras, Robert Andrews, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 3, 2021
Feeding intolerance in critically ill patients with COVID-19Rebecca Liu, Mary Paz, Layla Siraj, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled TrialDavid Isenberg, Richard Furie, Nicholas S Jones, et al.
Cell Reports. Medicine|July 25, 2023
An agonistic anti-signal regulatory protein α antibody for chronic inflammatory diseasesMarkus M Xie, Bingbing Dai, Jason A Hackney, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 9, 2005
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County StudyConstantine G Lyketsos, Leslie Toone, JoAnn Tschanz, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Journal of Medicinal Chemistry|October 24, 2022
Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 InhibitorChristopher McBride, Lynnie Trzoss, Davide Povero, et al.
JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.
Cell Reports|August 29, 2019
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response PhenotypesMyles J Lewis, Michael R Barnes, Kevin Blighe, et al.
Pageof 48